Michigan House Bill HB5350

Michigan 2023-2024 Regular Session

• Introduced: 11/14/23
• Refer: 11/14/23
• Refer: 1/10/24

Caption

Health: pharmaceuticals; drug manufacturers from engaging in certain conduct with pharmacies participating with a 340B program; prohibit. Amends 1978 PA 368 (MCL 333.1101 - 333.25211) by adding sec. 17757c.

Impact

If enacted, HB5350 would empower 340B entities by ensuring they receive fair pricing for medications purchased. It aims to protect these entities from discriminatory practices employed by manufacturers, thereby enhancing the overall efficacy of the 340B program in serving low-income and underserved populations. This legislation is designed to mitigate barriers that currently hinder pharmacies from delivering necessary medications at reduced costs, concurrent with their value in public health initiatives.

Summary

House Bill 5350 aims to amend the Public Health Code to establish regulations concerning pharmaceutical manufacturers and their interaction with pharmacies participating in the federal 340B drug pricing program. Specifically, the bill prohibits manufacturers from denying or limiting 340B pricing benefits, which are designed to give participating entities access to discounted medications. This provision is critical as it seeks to enhance the availability of affordable medications to healthcare providers that rely on the 340B program.

Contention

The introduction of HB5350 may lead to debates surrounding the implications for pharmaceutical manufacturers and the potential financial impact on the market. Proponents of the bill advocate for the increased accessibility it would provide, emphasizing the necessity for fair pricing practices. However, opponents may argue that the bill could infringe on manufacturers' pricing strategies and contract management, leading to potential conflict between public health interests and commercial operations.